Dermaliq

Dermaliq is a biotech company in Wilmington, United States, founded in 2021. It has raised $15.0M across 1 round, most recently a $15.0M Series A in January 2022.

Next-generation topical drug therapies for skin and follicular diseases

Employees
1–10
Founded
2021
Business Model
B2B
Total Funding
$15.0M
Last Round
$15.0M Series AJan 2022
Rounds
1

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 1 funding round and 1 investor for this company. The full record is or through the API.

About

Dermaliq Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company founded in 2021 as a spin-off from Novaliq GmbH to advance novel topical drug therapies in dermatology. The company's proprietary hyliQ™ technology platform enables cutaneous drug delivery with superior bioavailability compared to conventional topical formulations. Dermaliq's pipeline includes DLQ01 (topical androgenetic alopecia treatment targeting PGE2 receptors), DLQ02 (calcineurin inhibitor for plaque psoriasis), and DLQ03 (broad-spectrum topical antibiotic for skin and soft tissue infections). The company raised a USD 15 million Series A in January 2022 co-led by 3E Bioventures Capital and Beijing Whale Technology. Dermaliq is incorporated in Wilmington, Delaware and led by CEO Dr. Frank Löscher.

Summary

It lists 1–10 employees. It has raised $15.0M in total across 1 round, most recently a $15.0M Series A round in Jan 2022. Investors include 3E Bioventures Capital.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Data from Indexed.vcUpdated
Series ASeries AJan 2022
$15.0M

Investors

Similar Companies

Tiantan Biological / China Biologic (泰邦生物集团)

China's leading blood products manufacturer

Beijing, China1001–5000Biotech, Healthcare
Growth EquityTotal funding$5.1BAug 2022
Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.9BJan 2019
Warner ChilcottAcquired

Specialty pharmaceutical company

Rockaway, United States1001–5000Biotech, Healthcare
Private EquityTotal funding$3.0BJan 2004
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
Syneos HealthAcquired

Integrated biopharmaceutical solutions company

Burlington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.0BMay 2017
BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech, Oncology
Corporate RoundTotal funding$2.8BJan 2020

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Dermaliq on Indexed.vc
<a href="https://indexed.vc/companies/dermaliq"><img src="https://indexed.vc/api/badge/company/dermaliq" alt="Dermaliq on Indexed.vc" width="260" height="76" /></a>